title: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.
abstract: Cancer can be defined as a deregulation or hyperactivity in the ongoing network of intracellular and extracellular signaling events. Reverse phase protein microarray technology may offer a new opportunity to measure and profile these signaling pathways, providing data on post-translational phosphorylation events not obtainable by gene microarray analysis. Treatment of ovarian epithelial carcinoma almost always takes place in a metastatic setting since unfortunately the disease is often not detected until later stages. Thus, in addition to elucidation of the molecular network within a tumor specimen, critical questions are to what extent do signaling changes occur upon metastasis and are there common pathway elements that arise in the metastatic microenvironment. For individualized combinatorial therapy, ideal therapeutic selection based on proteomic mapping of phosphorylation end points may require evaluation of the patient's metastatic tissue. Extending these findings to the bedside will require the development of optimized protocols and reference standards. We have developed a reference standard based on a mixture of phosphorylated peptides to begin to address this challenge.
authors.affiliation: United States Food and Drug Administration (FDA)-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Sheehan
authors.forename: Valerie S
authors.initials: VS
authors.lastname: Calvert
authors.forename: Elaine W
authors.initials: EW
authors.lastname: Kay
authors.forename: Yiling
authors.initials: Y
authors.lastname: Lu
authors.forename: David
authors.initials: D
authors.lastname: Fishman
authors.forename: Virginia
authors.initials: V
authors.lastname: Espina
authors.forename: Joy
authors.initials: J
authors.lastname: Aquino
authors.forename: Runa
authors.initials: R
authors.lastname: Speer
authors.forename: Robyn
authors.initials: R
authors.lastname: Araujo
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.forename: Lance A
authors.initials: LA
authors.lastname: Liotta
authors.forename: Emanuel F
authors.initials: EF
authors.lastname: Petricoin
authors.forename: Julia D
authors.initials: JD
authors.lastname: Wulfkuhle
mesh_terms: D002277:Carcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008967:Molecular Biology / Q000379:methods*; D009362:Neoplasm Metastasis / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D010766:Phosphorylation; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods*; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015398:Signal Transduction
chemical_list: D010455:Peptides